Movymia (Teriparatide)

Teriparatide activates the PTH1 receptor on bone‑forming cells called osteoblasts. This activation triggers intracellular signaling pathways that increase osteoblast activity and number, leading to enhanced bone formation and remodeling. The net effect is an increase in bone mass and improved skeletal strength.

The specific dose and dosing schedule for Movymia are determined by the prescribing healthcare professional based on the patient’s clinical condition, weight, and response to therapy. Patients should follow the prescriber’s instructions and not alter the dose without medical guidance.

Safety of teriparatide in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To request Movymia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Movymia (teriparatide) is an anabolic agent that builds new bone, whereas many other osteoporosis drugs, such as bisphosphonates, are anti‑resorptive and primarily prevent bone loss. In patients with severe osteoporosis or those who have failed other therapies, teriparatide may offer greater increases in bone density and fracture risk reduction.

Movymia should be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 minutes.

Movymia is given as a subcutaneous injection, typically into the thigh or abdomen. The injection is performed by a trained healthcare professional or by the patient after proper instruction. The injection site should be rotated to minimize local reactions.

The most serious potential risks include the rare development of osteosarcoma, severe hypercalcemia, and serious allergic reactions such as anaphylaxis. Patients should be monitored regularly for signs of these conditions, and any concerning symptoms should be reported to a healthcare provider promptly.

Movymia is contraindicated in patients with a history of skeletal malignancies, bone metastases, or metabolic bone diseases such as Paget’s disease. It should also be avoided in individuals with hyperparathyroidism or those who are pregnant or breastfeeding unless the prescriber determines that the benefits outweigh the risks.